Recent Articles

Are you getting health care you don't need?

Could you benefit from wearing compression socks?

A low-tech school vacation: Keeping kids busy and happy without screens

Mold in the home: Identifying and treating the issue to prevent health problems

Effective, practical strategies for coping with urinary incontinence

Scalp psoriasis: What to know about this uncomfortable inflammatory skin condition

Measles is making a comeback: Can we stop it?

Should you be sleepmaxxing to boost health and happiness?

Need a root canal? Here's what to expect

Savoring the benefits of bone broth: Worth a taste?

Adam S. Cheifetz, MD

Contributor

Dr. Adam Cheifetz is director of the center for inflammatory bowel disease and medical director of infusion services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School. He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. He is involved in multiple research projects relating to IBD, and has published over 200 articles and chapters on the subject.

His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.